1 882

Cited 73 times in

Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.

DC Field Value Language
dc.contributor.author안정용-
dc.contributor.author안중배-
dc.date.accessioned2015-04-24T17:18:40Z-
dc.date.available2015-04-24T17:18:40Z-
dc.date.issued2009-
dc.identifier.issn0344-5704-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/105157-
dc.description.abstractBACKGROUND: Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, anti-angiogenesis, and apoptosis. This phase II trial evaluated the efficacy and toxicity profile of conventional FOLFIRI chemotherapy plus simvastatin in metastatic colorectal cancer patients. METHODS: Patients received irinotecan 180 mg/m(2) as a 90-min infusion followed by leucovorin 200 mg/m(2) in a 2-h infusion, and then 5-FU 400 mg/m(2) bolus injection followed by 2,400 mg/m(2) as a 46-h continuous infusion. Treatment cycles were repeated every 2 weeks until documented disease progression, unacceptable toxicity, or patient's refusal. Simvastatin 40 mg tablet was given once daily per oral everyday during the period of chemotherapy without a rest. RESULTS: From October 2005 to June 2006, 49 patients were enrolled. The overall response rate (ORR) was 46.9% (95% CI, 31.0-58.8) by intent-to-treat analysis and 45.8% (95% CI, 33.3-62.8) by per-protocol analysis. There were one complete response (CR) and 22 partial responses (PRs). Both CR and PRs were confirmed at least 4 weeks later. The disease-control rate was 83.7% (95% CI, 73.4-94.0). The median follow-up duration was 25.6 months (range, 20.9-28.8 months). The median survival of all patients was 21.8 months (95% CI, 14.4, 29.2). The median TTP was 9.9 months (95% CI, 6.4, 13.3). No patients experienced additional adverse effect that was definitely caused by simvastatin drug therapy in this trial. CONCLUSION: The combination of simvastatin plus FOLFIRI was a feasible regimen with promising antitumor activity.-
dc.description.statementOfResponsibilityopen-
dc.format.extent657~663-
dc.relation.isPartOfCANCER CHEMOTHERAPY AND PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/therapeutic use*-
dc.subject.MESHCamptothecin/administration & dosage-
dc.subject.MESHCamptothecin/analogs & derivatives-
dc.subject.MESHColorectal Neoplasms/drug therapy*-
dc.subject.MESHColorectal Neoplasms/pathology-
dc.subject.MESHFemale-
dc.subject.MESHFluorouracil/administration & dosage-
dc.subject.MESHHumans-
dc.subject.MESHLeucovorin/administration & dosage-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHSimvastatin/administration & dosage-
dc.titleSimvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurosurgery (신경외과학)-
dc.contributor.googleauthorJeeyun Lee-
dc.contributor.googleauthorKyung Hae Jung-
dc.contributor.googleauthorYoung Suk Park-
dc.contributor.googleauthorJoong Bae Ahn-
dc.contributor.googleauthorSang Jun Shin-
dc.contributor.googleauthorSeock-Ah Im-
dc.contributor.googleauthorDo Youn Oh-
dc.contributor.googleauthorDong Bok Shin-
dc.contributor.googleauthorTae Won Kim-
dc.contributor.googleauthorNamsu Lee-
dc.contributor.googleauthorJae Ho Byun-
dc.contributor.googleauthorYong Sang Hong-
dc.contributor.googleauthorJoon Oh Park-
dc.contributor.googleauthorSe Hoon Park-
dc.contributor.googleauthorHo Yeong Lim-
dc.contributor.googleauthorWon Ki Kang-
dc.identifier.doi10.1007/s00280-008-0913-5-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02260-
dc.contributor.localIdA02262-
dc.relation.journalcodeJ00437-
dc.identifier.eissn1432-0843-
dc.identifier.pmid19169686-
dc.identifier.urlhttp://link.springer.com/article/10.1007%2Fs00280-008-0913-5-
dc.contributor.alternativeNameAhn, Jung Yong-
dc.contributor.alternativeNameAhn, Joong Bae-
dc.contributor.affiliatedAuthorAhn, Jung Yong-
dc.contributor.affiliatedAuthorAhn, Joong Bae-
dc.citation.volume64-
dc.citation.number4-
dc.citation.startPage657-
dc.citation.endPage663-
dc.identifier.bibliographicCitationCANCER CHEMOTHERAPY AND PHARMACOLOGY, Vol.64(4) : 657-663, 2009-
dc.identifier.rimsid52735-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Neurosurgery (신경외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.